IL233086A0 - Use of n-hydroxysuccinimide to improve coupling stability - Google Patents
Use of n-hydroxysuccinimide to improve coupling stabilityInfo
- Publication number
- IL233086A0 IL233086A0 IL233086A IL23308614A IL233086A0 IL 233086 A0 IL233086 A0 IL 233086A0 IL 233086 A IL233086 A IL 233086A IL 23308614 A IL23308614 A IL 23308614A IL 233086 A0 IL233086 A0 IL 233086A0
- Authority
- IL
- Israel
- Prior art keywords
- hydroxysuccinimide
- conjugate stability
- improve conjugate
- improve
- stability
- Prior art date
Links
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570139P | 2011-12-13 | 2011-12-13 | |
| PCT/US2012/069527 WO2013090590A1 (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL233086A0 true IL233086A0 (en) | 2014-07-31 |
Family
ID=48613179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233086A IL233086A0 (en) | 2011-12-13 | 2014-06-12 | Use of n-hydroxysuccinimide to improve coupling stability |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140350228A1 (enExample) |
| EP (1) | EP2790724A4 (enExample) |
| JP (1) | JP2015504869A (enExample) |
| KR (1) | KR20140107418A (enExample) |
| CN (1) | CN104093425A (enExample) |
| AU (1) | AU2012352210A1 (enExample) |
| BR (1) | BR112014014464A2 (enExample) |
| CA (1) | CA2859444A1 (enExample) |
| EA (1) | EA201491173A1 (enExample) |
| HK (1) | HK1203364A1 (enExample) |
| IL (1) | IL233086A0 (enExample) |
| MX (1) | MX2014007125A (enExample) |
| SG (2) | SG10201604747WA (enExample) |
| WO (1) | WO2013090590A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101267841B (zh) | 2005-08-24 | 2012-10-10 | 免疫原公司 | 制备美登木素生物碱抗体缀合物的方法 |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| MX339927B (es) | 2011-03-29 | 2016-06-16 | Immunogen Inc | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. |
| SG11201502429YA (en) | 2012-10-04 | 2015-04-29 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| WO2014202775A1 (en) * | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN106267225B (zh) * | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
| WO2017178828A1 (en) | 2016-04-14 | 2017-10-19 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
| GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| CN113336823A (zh) * | 2021-05-28 | 2021-09-03 | 联宁（苏州）生物制药有限公司 | 一种用于抗体偶联药物连接子lnd1067的合成方法 |
| WO2025151380A1 (en) * | 2024-01-08 | 2025-07-17 | Azvlz, Inc. | Functionalized conjugation crosslinkers and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2835829B1 (fr) * | 2002-02-13 | 2007-09-14 | Centre Nat Rech Scient | Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications |
| DE10242076A1 (de) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | HAS-Allergen-Konjugate |
| CN101267841B (zh) * | 2005-08-24 | 2012-10-10 | 免疫原公司 | 制备美登木素生物碱抗体缀合物的方法 |
| WO2007059195A1 (en) * | 2005-11-14 | 2007-05-24 | University Of Southern California | Integrin-binding small molecules |
| ES2435779T3 (es) * | 2007-07-19 | 2013-12-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico |
| CN105198908B (zh) * | 2009-02-05 | 2019-12-24 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| SG10201810743WA (en) * | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
-
2012
- 2012-12-13 CN CN201280068773.2A patent/CN104093425A/zh active Pending
- 2012-12-13 HK HK15103864.0A patent/HK1203364A1/xx unknown
- 2012-12-13 WO PCT/US2012/069527 patent/WO2013090590A1/en not_active Ceased
- 2012-12-13 EA EA201491173A patent/EA201491173A1/ru unknown
- 2012-12-13 AU AU2012352210A patent/AU2012352210A1/en not_active Abandoned
- 2012-12-13 SG SG10201604747WA patent/SG10201604747WA/en unknown
- 2012-12-13 BR BR112014014464A patent/BR112014014464A2/pt not_active IP Right Cessation
- 2012-12-13 CA CA 2859444 patent/CA2859444A1/en not_active Abandoned
- 2012-12-13 MX MX2014007125A patent/MX2014007125A/es unknown
- 2012-12-13 SG SG11201403179QA patent/SG11201403179QA/en unknown
- 2012-12-13 KR KR20147019143A patent/KR20140107418A/ko not_active Withdrawn
- 2012-12-13 JP JP2014547433A patent/JP2015504869A/ja active Pending
- 2012-12-13 US US14/365,305 patent/US20140350228A1/en not_active Abandoned
- 2012-12-13 EP EP12856692.4A patent/EP2790724A4/en not_active Withdrawn
-
2014
- 2014-06-12 IL IL233086A patent/IL233086A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201604747WA (en) | 2016-08-30 |
| CN104093425A (zh) | 2014-10-08 |
| EP2790724A1 (en) | 2014-10-22 |
| HK1203364A1 (en) | 2015-10-30 |
| BR112014014464A8 (pt) | 2017-06-13 |
| BR112014014464A2 (pt) | 2017-06-13 |
| WO2013090590A1 (en) | 2013-06-20 |
| CA2859444A1 (en) | 2013-06-20 |
| EA201491173A1 (ru) | 2014-11-28 |
| US20140350228A1 (en) | 2014-11-27 |
| SG11201403179QA (en) | 2014-07-30 |
| AU2012352210A1 (en) | 2014-07-24 |
| JP2015504869A (ja) | 2015-02-16 |
| MX2014007125A (es) | 2015-04-16 |
| KR20140107418A (ko) | 2014-09-04 |
| EP2790724A4 (en) | 2015-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265707A (en) | Pharmaceutical preparations containing human antibodies to pcsk9 | |
| HUE043976T2 (hu) | Konjugátumok elõállítására szolgáló eljárások | |
| IL233086A0 (en) | Use of n-hydroxysuccinimide to improve coupling stability | |
| HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
| SI2709986T1 (sl) | Devterirani derivati ivakaftorja | |
| IL227333B (en) | A method for preparing glycosphingolipids and their uses | |
| ZA201404077B (en) | Neutralizing antibodies to hiv -1 and their use | |
| EP2892577A4 (en) | METHOD OF TISSUE GENERATION | |
| CO6960555A2 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| EP2680848A4 (en) | STABLE TETRAHYDROBIOPTERINE COMPOSITIONS | |
| EP2764325A4 (en) | USE OF A VIDEOGRAMMETRY FOR THE MANUFACTURE OF PARTS | |
| PL2690985T3 (pl) | Mebel | |
| EP2852403A4 (en) | METHOD FOR MODIFYING TISSUE | |
| EP2760853A4 (en) | NEW SALTS OF ALOGLIPTIN | |
| GB201501016D0 (en) | Preparation of 18F-fluciclovine | |
| GB2491882B (en) | Improvements to letterboxes | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| GB2488327B (en) | Structure of brewing device | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| EP2731999A4 (en) | PERMANENT FIXING OF MEANS OF SURFACES WITH C-H FUNCTIONALITY | |
| PL395425A1 (pl) | Sposób wytwarzania chlorowodorku 2-amino-N-tert-butylo-2- cyjanoacetamidu | |
| EP2716013A4 (en) | CIRCUITRY FOR MAINTAINING CORRELATION BETWEEN ADDRESS SETS | |
| GB201104632D0 (en) | Use of medicament | |
| PL395618A1 (pl) | Urzadzenie do stabilizacyjnego wzmacniania wlókien miesni | |
| IL212131A0 (en) | Two halves of ahearf are joimed to test acoople's comptisility |